Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma? - Wikidata - awgldk - TriplyDB

Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?

Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?

http://www.wikidata.org/entity/Q39294879

about

Unlocking the NF-κB Conundrum: Embracing Complexity to Achieve Specificity.Transplant strategies in relapsed/refractory Hodgkin lymphoma.

P2860

Q52538370-FAA4EBCA-A810-47B6-A5F5-9186B149BF90 Q52676516-764FB64E-3A73-4758-A9E7-5EF4700BBA58

P2860

Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?

http://www.wikidata.org/entity/Q39294879

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?

@en

Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?

@nl

type

label

Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?

@en

Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?

@nl

prefLabel

Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?

@en

Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?

@nl

P1433

Q39294879-464ABFF4-0DAB-404D-A5EF-E59AE89C64F1

P1476

Q39294879-3B719C0F-C432-4008-A84F-7EC01EF8E11E

P2093

Q39294879-3894BE85-DBF8-4CBF-B66C-92E1691C7CF9

P2860

Q39294879-17AF955F-035D-4A2A-930E-0B310DD5E745

Q39294879-1F8F9F7B-9BBF-415C-A5E3-315DC7BD1802

Q39294879-1FD01CF9-B40A-4146-B493-25B083998FDA

Q39294879-220D3351-D26D-4870-A9F7-E053C7226AC8

Q39294879-248F98A7-B8D4-4BAF-8378-65148A7DDF54

Q39294879-2782013C-8F49-4B85-9BF0-08DF1ECF3B88

Q39294879-2DC6F3DE-09C3-4237-9ADC-305878367656

Q39294879-2F92ADA3-24A0-4635-9B12-1916F7FFB7A3

Q39294879-3224498A-EDE9-458F-8C43-8326BB930CE6

Q39294879-3C76A921-E946-48F4-A681-1201DAA14E54

P2888

Q39294879-15CDBCC7-9939-40C7-97D1-B773D697EE6C

P304

Q39294879-90B440CC-A125-4840-8996-C2B6BEF44B4D

P31

Q39294879-475FB3B5-2A2C-46A8-9144-0D714648D4CD

P356

Q39294879-1980573B-7718-49E4-98BE-830A6EF92E19

P433

Q39294879-937ACE9B-2402-4511-98BB-060AA91462BA

P478

Q39294879-A9C8D7A4-6085-453A-8E17-BC70C62913B2

P50

Q39294879-BF1A1336-4945-4C1F-A2A5-EA66B7B28827

P577

Q39294879-B75DF1F0-0738-4F3F-8A81-2C063927794B

P698

Q39294879-CE4C1430-E23E-4A8C-92BF-122811D21F59

P356

S11899-017-0384-Z

P1433

Current hematologic malignancy reports

P1476

Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?

@en

P2093

Alison J Moskowitz

http://www.w3.org/2001/XMLSchema#string

P2860

PD-1 and its ligands in tolerance and immunity

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.

Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.

A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma.

Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma.

Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study.

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.

PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma.

P2888

s11899-017-0384-z

P304

227-233

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11899-017-0384-Z

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-05-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28488185

http://www.w3.org/2001/XMLSchema#string